The agreement comes at a time when several pharmaceutical groups are facing a sharp decline in sales of Covid-19 vaccines.
The Sanofi and Novavax groups, once rivals in the manufacture of the Covid-19 vaccine, sealed an alliancesealed an alliance through which, starting in 2025, Sanofi will market the coronavirus vaccine from its American rival Novavax.
In a joint statement they indicated that the French Sanofi, which will acquire a small part of the American company (less than 5%), may also develop a combined vaccine against flu and Covid-19, based on that of Novavax.
“Novavax will receive an initial payment of $500 million and up to $700 million (additional)” by Sanofi, the note details.
This agreement was concluded at a time when Several pharmaceutical groups are facing a sharp decline in sales of Covid-19 vaccines.
The British pharmaceutical giant AstraZeneca announced on Wednesday that it is withdrawing Vaxzevria from saleone of the first vaccines against the virus to hit the market during the pandemic, due to the drop in demand.
As for Novavax and Sanofi, their agreement answers different questions for the two groups.
For the American company, a small company whose portfolio largely depends on the Covid-19 vaccine, it represents valuable help.
Sanofi, a giant in the sector for which the drop in sales of Covid vaccines does not pose a threat, will, for its part, be able bet on combined vaccination against Covid-19 and flu.
Source: Ambito
